TITLE

Therapeutics in Respiratory Disease

PUB. DATE
April 1995
SOURCE
Thorax;Apr1995, Vol. 50 Issue 4, p430
SOURCE TYPE
Review
DOC. TYPE
Book Review
ABSTRACT
No abstract available.
ACCESSION #
66066497

 

Related Articles

  • Therapeutics in Respiratory Disease (Book Review). Taylor, D.R. // BMJ: British Medical Journal (International Edition);12/10/94, Vol. 309 Issue 6968, p1590 

    Reviews the book 'Therapeutics in Respiratory Disease,' by Peter J. Barnes, Kian Fan Chung, Timothy W. Evans and Steven G. Spiro.

  • Astra buys lung drug group for £740m.  // Daily Mail;6/11/2013, p67 

    PHARMACEUTICALS giant AstraZeneca is buying California-based Pearl Therapeutics, a privately held company focused on the development of inhaled drugs for respiratory diseases.

  • Andrographis paniculata. Barilla, Jean // Better Nutrition;Jun99, Vol. 61 Issue 6, p26 

    Presents information on the herb Andrographis paniculata and its therapeutic benefits. Use for the treatment of an array of upper respiratory and chronic diseases; Immune system stimulator; Fever reducer.

  • Vetoquinol launches one-shot Marbocyl Solo.  // Irish Veterinary Journal;Nov2007, Vol. 60 Issue 11, p650 

    The article introduces the Marbocyl Solo, which is a one-shot antibiotic therapeutic for bovine respiratory disease, from Vetoquinol UK & Ireland.

  • Treatment of chronic respiratory diseases in obese people. Mascitelli, Luca; Pezzetta, Francesca // CMAJ: Canadian Medical Association Journal;4/10/2007, Vol. 176 Issue 8, p1130 

    A letter to the editor is presented in response to the article "The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies," by Magali Poulain and others in the 2006 issue.

  • The Respiratory Disease Pipeline: A Competitive Review 2011 Surveys 105 Physicians 51 Pulmonologists and 54 PCPs.  // Biomedical Market Newsletter;10/26/2011, Vol. 21, p963 

    The article mentions the release of Respiratory Disease Pipeline: A Competitive Review report. The report examines the respiratory disease pipeline, the companies involved in the development of these agents, and the opinions of 105 surveyed pulmonologists and primary care physicians (PCPs). The...

  • Young anesthesiologists, be a frontline respiratory researcher. Isono, Shiroh; Yamakage, Michiaki // Journal of Anesthesia;2011, Vol. 25 Issue 1, p144 

    The articles emphasizes the contributions of pioneer anesthesiologists in the study and inventions of medical instruments and apparatus for the management of patients with respiratory organ diseases. The author notes that these pioneering efforts have helped in explaining the causes, diagnostics...

  • MANAGEMENTUL PACIENTULUI OBEZ CU BOLI OBSTRUCTIVE CRONICE. Mihălţan, Florin // Internal Medicine / Medicina Interna;Apr2014, Vol. 11 Issue 2, p53 

    Management of such patients is extremely difficult due to interference of chronic obstructive respiratory disease and obesity. Reviewing the prevalence of these diseases, the effects of obesity on respiratory function allows us to identify common causal factors, therapeutic options and treatment...

  • Other News.  // Applied Clinical Trials;Jul2006, Vol. 15 Issue 7, p50 

    The article reports on the addition of endocrinology and metabolic disease as part of the Basking Rick, NJ company, i3 Research's therapeutic armentarium of oncology, respiratory and infectious diseases. This addition to the company's core therapeutic area was announced at the DIA 42nd Annual...

  • JUST BREATHE: COPD, ASTHMA FUTURE.  // Applied Clinical Trials;Jun2010, Vol. 19 Issue 6, p18 

    The article reports that COPD and asthma comprise 32 billion dollars and will increase in 2016 due to growing disease awareness of patients in respiratory therapeutic market, according to IMS Health 2009 data.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics